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The human colon carcinoma cell line Caco-2 spontaneously undergoes enterocytic differentiation in culture. We used sodium butyrate to modify 
differentiation and growth properties of this cell line and considered c-myc expression as a potential target. Degradation of normal c-myc mRNAs 
with a half-life of 20 min is not coupled to translation in this cell line, as determined by cycloheximide treatment. We show that butyrate reduces 
c-myc mRNA levels after a 30 min delay. Butyrate does not affect c-myc expression at the level of transcriptional initiation or elongation, as 
determined by run-on analysis, but at a post-transcriptional level. Cycloheximide blocks butyrate-dependent reduction of c-myc mRNA levels. 
Cross-linking experiments show that a 34 kDa protein binds specifically to the c-rnyc AU-rich instability determinant found in the 3’-untranslated 
region (ARE). Binding of this protein to the ARE is not modulated by butyrate or cycloheximide. These experiments suggest that butyrate induces 
a factor involved in c-myc’ mRNA degradation that differs from the known ARE-associated proteins. Post-transcriptional modification of gene 
expression could be one of the major targets for this anti-proliferative agent. 
c-myc; Butyrate: Caco-2; Cross-link; mRNA stability; Run-on 
1. INTRODUCTION 
The human colon carcinoma cell line Caco-2 [I] spon- 
taneously differentiates into enterocytes in culture [2]. 
Under standard culture conditions, Caco-2 cells form 
confluent monolayers consisting of well polarized co- 
lumnar cells with tight junctions and a typical apical 
brush border [3]. Hydrolases associated with the small 
intestinal brush border, such as sucrase-isomaltase, lac- 
tase, and aminopeptidase are also expressed [4]. 
Polar organic solvents, such as butyric acid, a four- 
carbon fatty acid, have been used to modify the growth 
and differentiation properties of cells in culture [5]. Bu- 
tyric acid is a natural fermentation product of the colon 
microflora [6,7]. Butyric acid treatment of cultured cells 
creates major modifications in chromatin structure and 
cytoskeletal assembly, and alterations in cell morphol- 
ogy, growth rate, DNA synthesis, enzymatic activities 
and expression of different mammalian genes without 
affecting the level of protein synthesis [5]. In colon car- 
cinoma cell lines, butyric acid induces expression of the 
carcinoembryonic antigen gene (CEA) [8] and of a pla- 
cental-type alkaline phosphatase [9]. It was suggested 
that butyrate-induced gene expression was caused by 
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alterations in chromatin structure through histone ace- 
tylation, as measured by the increased sensitivity of 
chromatin to DNase I digestion [lo]. However, no cor- 
relation has been found between changes in nuclease 
sensitivity and induction of gene expression, as a result 
of butyrate treatment [l 11. 
Recent reports have suggested that butyric acid can 
modulate gene expression through specific promoter re- 
gions. In murine erythroleukemia cells, a 156 bp pro- 
moter fragment was found to be necessary for butyrate 
dependent activation of the chicken embryonic globin 
gene [12]. Sequences containing Spl transcription factor 
binding sites were defined as a butyrate-inducible region 
in the human immunodeficiency virus (HIV) type I long 
terminal repeat [ 131. 
In order to understand the effects of butyrate on 
proliferation and gene expression, we considered c-myc 
proto-oncogene expression as a potential target for bu- 
tyric acid in the colon carcinoma cell line Caco-2. C-myc 
gene expression has been linked to the control of cell 
proliferation, differentiation and apoptosis [ 141. This 
transcription factor, which forms an heterodimer com- 
plex with the product of the max gene [ 151, is one of a 
number of cellular genes whose expression is rapidly 
induced during the GO to Gl transition by multiple 
mitogenic stimuli, independent of de novo synthesis 
[14]. C-myc expression is rapidly down-regulated after 
induction of differentiation in many cell types [14,16]. 
We show here that c-myc mRNA turnover in Caco-2 
cells is independent of translation and that butyrate 
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Fig. 1. (a) Effect of cycloheximide (Cyx) on c-myc mRNA steady-state levels. Cytoplasmic RNAs were isolated from Caco-2 cells grown in medium 
without serum and treated for the indicated times (04 h) with 40 ,@ml Cyx. RNAs transferred to a nylon membrane were hybridized to a c-m,vc 
specific RNA probe. The filter was rehybridized to a human /I-actin DNA probe, as a control for RNA loading. b. Half-life of c-m~lc mRNAs. 
Cytoplasmic RNAs were isolated from Caco-2 cells treated for the indicated times (O--2 h) with 10 &ml actinomycin D (Act D). RNAs were 
hybridized to a c-myc specific RNA probe and rehybridized to a 28s DNA probe, as a control for RNA loading. Half-life was measured by scanning 
densitometry. 
reduces c-myc mRNA levels by a post-transcriptional 
mechanism requiring new protein synthesis. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
The human enterocyte-like cell line Caco-2215 used as a model to 
study intestinal cell differentiation and function in vitro was obtained 
from A. Quaroni (Cornell University, Ithaca, NY). This clone derived 
from the parent Caco-2 cell line (HTB 37; ATCC, Rockville, MD) has 
been characterized elsewhere [17]. Cells were grown in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 10% fetal bo- 
vine serum (FBS). 24 h prior to sodium butyrate treatment, medium 
was changed to DMEM without serum. Sodium butyrate (Sigma), at 
a 5 mM final concentration, was added to cells at 70-80% confluency. 
Cycloheximide and actinomycin D (Sigma) were used respectively at 
concentrations of 40 and 10 ,@ml. 
2.2. RNA isolation and analysis 
Cytoplasmic RNAs were prepared by the urea method [IS] and 
denatured with formaldehyde for Northern blot analysis [19]. Hybrid- 
izations were performed with the following probes: a 1.3 kb C[aI- 
EcoRI human c-myc fragment containing the third exon and the 3’- 
untranslated sequences [20]; a human/I-actin HindIII-EcoRI fragment 
[21] and a human 28s ribosomal RNA probe (ATCC 77235). 
2.3. Nuclear run-on assays 
Cells were resuspended in phosphate-buffered saline, centrifuged 
and lysed in 0.5 ml of buffer A (0.3 M sucrose, 60 mM KCI, 15 mM 
NaCI, 15 mM HEPES (pH 7.5), 2 mM EDTA, 5 mM EGTA, 15 mM 
spermine, 0.5 mM spermidine, 14 mM mercaptoethanol, 0.25% Non- 
idet P-40) [22]. After centrifugation, the supernatant was recovered for 
cytoplasmic RNA purification. The nuclei were resuspended in nuclei 
storage buffer [22] containing 100 U of RNasin (Promega) per ml. 
Nascent transcripts were elongated in vitro for 30 min at 26°C with 
[a-“P]UTP, and run-on analysis was performed as described previ- 
ously [23]. The labeled nuclear RNAs were hybridized to the following 
DNAs: mycA, a 604 bp SmaI-PvuII human c-m_vc fragment represent- 
ing the first exon (103 U); mycB, a 1.3 kb ClaI-EcoRI human c-myc 
fragment containing the third exon and the 3’-untranslated region (199 
U) [20]; GAPDH, a PstI fragment of the rat glyceraldehyde-3-phos- 
phate dehydrogenase gene [24]. Signal intensity was quantitated by 
densitometry with a Pharmacia LKB XL Ultroscan. 
2.4. L/V cross-linking and label transjir 
A 1.3 kb ClaI-EcoRI human c-rn~c fragment encompassing the 
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third exon and the 3’-untranslated region [20] was subcloned in the 
pSP72 vector (Promega). The plasmid was linearized either with NsiI 
@AU, 634 nt transcript) or SspI (containing the AU-rich region, 830 
nt transcript). Linearized plasmids were transcribed in vitro with 
bacteriophage RNA polymerase T7 according to Promega instruc- 
tions. Labeled RNA transcripts were produced by incorporation of 
[a-“P]UTP. Unlabeled RNAs were transcribed in a similar fashion 
except that the labeled nucleotide was replaced by 500 PM UTP. 
Cytoplasmic extracts were prepared from untreated and butyrate- 
treated Caco-2 cells in a lysis buffer containing 10 mM HEPES (pH 
7.9) I mM EDTA, 60 mM KCl, 1 mM dithiothreitol (DTT). 0.25% 
Nonidet P-40 and I mM phenylmethylsulfonylfluoride (PMSF). Nu- 
clei were pelleted by centrifugation at 14,000 x g for 2 min. The super- 
natant was mixed to 0.5 volume of resuspension buffer containing 0.25 
M Tris-HCl (pH 7.8) 60 mM KCI, 1 mM DTT, 1 mM PMSF [25]. 
Cytoplasmic extracts were immediately frozen in dry ice and stored 
at -70°C. 
Cytoplasmic extracts (20 pug) were incubated at room temperature 
for 20 min with “P-labeled RNA in a buffer containing 1 mM MgCl?, 
0.25 mM DTT, 10 mM HEPES (pH 7.9) 5 pg tRNA and 5% glycerol 
in a total volume of 15 ~1. The reaction mixtures were transferred into 
a 96-well culture dish and were cross-linked for 4 min at 254 nm with 
a UV DNA transfer lamp (Fotodyne). RNase A was added at a 1 
mg/ml final concentration and reactions were incubated at 37°C for 
15 min [26]. Samples were heated at 100°C for 3 min in an equal 
volume of loading buffer and separated by electrophoresis on a SDS- 
polyacrylamide gel. “P-labeled proteins were visualized by autoradi- 
ography. 
3. RESULTS AND DISCUSSION 
Sodium butyrate treatment of Caco-2 cells results in 
growth inhibition and cellular and genetic alterations 
that affect the normal differentiation pathways (data 
not shown). These dramatic effects on proliferation and 
differentiation by butyrate, also found in other colon 
carcinoma cell lines [8,9], led us to consider c-myc as a 
potential target for butyric acid. C-myc transient accu- 
mulation is due first to its transcriptional activation and 
to the extreme instability of the mRNA transcripts 
[ 14,161. C-myc steady-state mRNA levels in Caco-2 cells 
are unaffected in medium with or without serum (data 
not shown). Since c-myc expression does not seem to 
Volume 326, number 1,2,3 FEBS LETTERS July 1993 
a 
NaBu 
, I 
0 lh 2h 4h 
mycA 
mycB 
GAPDH 
b 
Fig. 2. (a) Effect of butyrate and cycloheximide on c-myc expression. 
Cytoplasmic RNAs were isolated from Caco-2 cells grown in medium 
without serum and treated for the indicated times (04 h) with 5 mM 
sodium butyrate alone (NaBu) or in combination with 40,&ml cyclo- 
heximide (NaBu+C). RNAs were hybridized to a c-myc RNA probe 
and rehybridized to a /Sactin DNA probe, as a control for RNA 
loading. (b) Effect of butyrate on c-myc transcription. Nuclear run-on 
assays were performed as described previously [23]. Nuclei were iso- 
lated from Caco-2 butyrate-treated cells at the indicated times (I, 2 
and 4 h). Labeled nuclear RNAs were hybridized to the following 
probes: mycA, a 604 bp SmaI-PvuII human c-myc fragment contain- 
ing first exon sequences [20]; mycB, a 1.3 kb CluI-EcoRI human c-myc 
fragment encompassing the third exon and the 3’-untranslated region 
[20]; GAPDH, a PstI fragment of the rat glyceraldehyde-3-phosphate 
dehydrogenase [24]. 
respond normally to serum components, we verified the 
effect of the protein synthesis inhibitor cycloheximide 
on its regulation. Inhibition of protein synthesis results 
in an increase in c-myc mRNA levels in most cell lines 
[ 161 because of translation-dependent control of mRNA 
stability [27-291. Northern analysis of mRNAs isolated 
from Caco-2 cells treated with cycloheximide shows 
that c-myc mRNA levels do not increase in response to 
the inhibitor (Fig. la). This is consistent with results 
obtained with other colon carcinoma cell lines [30]. 
Half-life of c-myc mRNAs was measured after treat- 
ment of Caco-2 cells with the transcription inhibitor 
actinomycin D. Scanning densitometry shows a short 
half-life of 20 min (Fig. lb). Thus, c-myc half-life is 
determined by mechanisms of stability unaffected by 
protein synthesis inhibitors in Caco-2 cells. This sug- 
gests that rapid c-myc mRNA degradation in this colon 
carcinoma cell line does not require translation of the 
mRNA, as opposed to its regulation in other cell lines 
[14,16,27-291. 
Northern analysis of cytoplasmic RNAs isolated 
from cells treated for different times in medium without 
serum and containing 5 mM sodium butyrate shows an 
abrupt decrease in c-myc mRNA levels after a lag time 
of 30 min (Fig. 2a). These repressed levels remained 
constant, as long as butyrate was present, as determined 
by densitometry and comparison to the p-actin control 
(Fig. 2a, data not shown). Interestingly, addition of 
cycloheximide to butyrate-treated cells restored c-myc 
mRNA levels (Fig. 2a). To determine whether butyrate 
was modulating c-myc expression at the level of tran- 
scriptional initiation, we performed run-on transcrip- 
tion assays with nuclei from butyrate-treated Caco-2 
cells. Equal counts of nascent radioactively labeled 
transcripts were hybridized to c-myc first exon (mycA), 
c-myc third exon and 3’-untranslated region (mycB), 
and GAPDH DNA fragments immobilized on nitrocel- 
lulose filters. Scanning densitometry with comparison 
to the GAPDH control shows that butyrate does not 
affect c-myc transcription at the level of initiation (see 
mycA, Fig. 2b). Furthermore, butyrate does not modu- 
late the transcriptional block to elongation [14], as 
shown by comparison of signal intensities of mycA up- 
stream and mycB downstream probes, and after taking 
into account the number of uridines in each probe (Fig. 
2b). Scanning densitometry shows variations in the 
mycA:mycB ratio from 2.5 to 4.1 from one experiment 
to the other, with or without butyrate (n = 4). A weak 
block to elongation has also been found in the human 
colon carcinoma cell line COLO 320 HSR [31]. These 
data suggest that butyrate does not repress c-myc ex- 
pression at the level of initiation or elongation. In fact, 
post-transcriptional mechanisms seem to account for 
the delayed reduction of c-myc mRNA transcripts. Bu- 
tyrate could induce a nuclease or a protein targeting 
c-myc mRNAs to a degradation pathway other than the 
cycloheximide-independent pathway normally found in 
Caco-2 cells. This induction depends on new protein 
synthesis since cycloheximide, a protein synthesis inhib- 
itor, restores the normal mRNA levels in the presence 
of butyrate. 
Two distinct determinants have been implicated in 
the control of c-myc mRNA stability. One element con- 
sists of AU-rich sequences found in the 3’-untranslated 
region of the c-fos and c-myc proto-oncogenes, and of 
lymphokine genes [29,32-341. These AU-rich elements 
(ARE) bind multiple proteins, including proteins of 32- 
37 kDa [35537], and are not required in certain condi- 
tions for rapid c-myc mRNA degradation [38,39] be- 
cause of the presence of other instability determinants. 
Interaction between the ARE and these proteins corre- 
lates with mRNA instability [35-371. The second ele- 
ment localized in the third exon coding region [27,28] 
is a 182 nt fragment from the carboxy-terminal portion 
of the c-myc coding region which binds to a 75 kDa 
polysome-associated protein [40]. This sequence en- 
codes a helix-loop-helix (HLH) domain implicated in 
47 
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Fig. 3. UV-induced cross-linking of a 34 kDa protein to c-myc transcripts in vitro. RNAs transcribed in vitro with [a-“P]UTP from a 830 bp 
&I-SspI c-myc fragment were incubated in vitro with Caco-2 cell cytoplasmic extracts and irradiated with UV light. Reaction mixtures were 
incubated with RNase A and separated on SDS polyacrylamide gel. (A) Radiolabeled c-myc RNA and lOO-fold molar excess of either a 830 nt 
c-myc RNA containing the ARE (+AU) or a 634 nt transcript without the ARE (+dAU) were incubated with cytoplasmic extracts. (B) Radiolabeled 
c-myc RNA was incubated with cytoplasmic extracts obtained from cells treated for 0.54 h with 5 mM sodium butyrate (NaBu). 
transcription factor dimerization [41]. It has been sug- 
gested that the 75 kDa protein protects this region from 
endonuclease attack [40]. To assess whether these pro- 
teins could be modulated by butyrate, thus explaining 
the increased instability of c-myc mRNAs in the pres- 
ence of butyrate, we performed cross-linking experi- 
ments. 
Cytoplasmic extracts were prepared from Caco-2 
cells grown in medium without serum and were incu- 
bated with a 32P-labeled riboprobe consisting of 830 
nucleotides from the third exon and 3’-untranslated re- 
gion of the c-myc gene [20]. To determine the specificity 
of this binding, lOO-fold molar excess of unlabeled 
RNA with (+AU) or without (+dAU) AU-rich se- 
quences between the NsiI and SspI sites was used to 
compete for these complexes. The reaction mixtures 
were cross-linked by UV irradiation and incubated with 
RNase A. The labeled complexes were separated by 
electrophoresis on 10% SDS-polyacrylamide gels. Unla- 
beled c-myc RNA containing the AU-rich region effi- 
ciently competes for a 34 kDa protein present in Caco-2 
cytoplasmic extracts (Fig. 3A). These data suggest that 
this factor binds specifically to AU-rich sequences in the 
c-myc 3’-untranslated region. The’same or related pro- 
teins have been found to bind to ARE sequences in 
other genes [35-371. 
Cytoplasmic extracts were prepared from Caco-2 
cells treated with 5 mM sodium butyrate in medium 
without serum. The cross-linking experiment in Fig. 3B 
shows that butyrate does not modulate the RNA bind- 
ing activity of the 34 kDa protein (Fig. 3B), nor does 
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cycloheximide (data not shown). These data therefore 
suggest that reduction in c-myc mRNA levels caused by 
butyrate does not involve the 34 kDa protein associated 
with the AU-rich instability determinant. 
Actinomycin D can block mRNA decay mediated by 
the c-fos ARE [33] but not by the c-myc ARE [28]. 
However, actinomycin D does in fact inhibit turnover 
mediated by the mRNA translation-dependent destabil- 
izing element found in the c-myc third exon protein- 
coding sequence, in serum-stimulated cells [28]. Re- 
cently, You et al. [42] have observed a reduced binding 
activity of a 37 kDa protein to the c-fos ARE sequence 
after actinomycin D treatment. We thus verified if acti- 
nomycin D could affect the binding activity of the 37 
kDa protein to the c-myc ARE. Cytoplasmic extracts 
were prepared as before from Caco-2 cells grown in 
serum-free medium with actinomycin D, in the presence 
or absence of butyrate. These extracts were incubated 
with the 830 nt labeled c-myc transcript, cross-linked 
and loaded on a SDS-polyacrylamide gel. Interestingly, 
actinomycin D, with or without butyrate, induced DNA 
binding activities of multiple proteins, including the 37 
kDa protein and proteins of 88, 74, 44 and 41 kDa. 
Recently, Savant-Bhonsale and Cleveland [43] have pre- 
sented evidence of a > 20s degradation complex impli- 
cated in mRNA instability through AU motifs for gran- 
ulocyte monocyte colony stimulating factor mRNA. In- 
hibition of transcription by actinomycin D results in 
measured half-lives that cannot account for differences 
in RNA accumulation of certain mutants. They have 
suggested that transcription may be required for 
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Fig. 4. Effect of actinomycin D on protein binding to c-myc transcripts 
in vitro. Cytoplasmic extracts were isolated from Caco-2 cells grown 
in medium without serum and treated with 10 pg/rnl actinomycin D 
alone (A) or in combination with 5 mM sodium butyrate (B). Labeled 
transcripts from a 830 bp &I-SspI c-myc fragment containing the 
third exon and 3’.untranslated sequences were incubated with cyto- 
plasmic extracts. Reaction mixtures were UV cross-linked, incubated 
with RNase A and fractionated on a SDS-polyacrylamide gel. 
mRNA degradation because a short-lived RNA is in- 
volved directly or indirectly in the AU-dependent degra- 
dation pathway [43]. The labeled proteins appearing 
after actinomycin D treatment of Caco-2 cells could be 
bound to unstable RNAs. Degradation of these RNAs 
after transcriptional arrest would allow these proteins 
to interact with c-myc labeled RNAs. Proteins of 37, 66, 
71 and 82 kDa have been found to interact with the c-fos 
ARE [37,42]. Proteins of 32-37 and 40 kDa interact 
with c-myc AU-rich sequences [35537]. Whether these 
proteins are the same as those that bind c-myc RNA in 
response to actinomycin D in Caco-2 cells is not known. 
We have shown here that c-myc mRNA turnover in 
a human colon carcinoma cell line is independent of 
translation since cycloheximide treatment does not re- 
sult in an increase in steady-state mRNA levels, as seen 
in other systems [ 161. Butyric acid, a known anti-prolif- 
eration and differentiation agent, causes an important 
decrease in steady-state c-myc mRNA levels after a 30 
min delay. Translation inhibitor cycloheximide reverses 
butyric acid’s effect however. Taken together, these re- 
sults suggest that butyrate induces transcription of a 
factor involved in the control of c-myc expression. Al- 
ternatively, butyrate could induce small unstable RNAs 
part of a degradation complex. Since butyric acid does 
not affect c-myc expression at the level of transcrip- 
tional initiation or elongation, this factor probably reg- 
ulates c-myc expression at a post-transcriptional level. 
The major post-transcriptional mechanism implicated 
in c-myc regulation occurs at the level of mRNA stabil- 
ity [ 14,161. We have shown that butyrate does not affect 
the binding activity of a 34 kDa protein to c-myc AU- 
rich sequences (ARE) implicated in mRNA degrada- 
tion. Butyric acid could induce a nuclease involved in 
mRNA degradation. Endonuclease attack could occur 
through the ARE or c-myc coding region determinants 
[28,35,40]. C-myc mRNA instability dependent on bu- 
tyrate seems to be specific since C--OS mRNA levels are 
induced rapidly by butyrate at a post-transcriptional 
level (data not shown). The c-myc coding region deter- 
minant differs from the analogous element in c-fos by 
the presence of an HLH region and thus could be a 
target for butyrate dependent c-myc mRNA regulation. 
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